Sign in

Pauline Funchain

@funchainmd.bsky.social
4.2K followers 1K following 278 posts

Melanoma oncology @Stanford. Study hereditary genetics and irAEs. LA explant in SF via Ohio State, NIH/NHGRI, Harbor UCLA, and Cleveland Clinic. Sports fan, geek and mom. APD Hem/Onc fellowship. ASPirE founder, Checkpoint Now. COI bit.ly/43UCDOz

PostsRepliesMedia
Pauline Funchain @funchainmd.bsky.social · 20/05/2026
Straight up fangirling here at Medicine Grand Rounds @stanfordmedicine.bsky.social Mix of emotions as Fauci goes through the history of HIV, paralleling many of our medical lives and training. How many lost in the decades before, and how no one should be lost today - except for infrastructure gaps 😢
030 0
Pauline Funchain @funchainmd.bsky.social · 24/03/2026
One of the wonderful things about doing science @stanford-cancer.bsky.social is incredible support through multiple shared resources supported by SCI. Today highlighting the new Organoid Core led by Claudia Petrisch and Cancer Data Science Core led by Summer Han #SCIResearch26
020 0
Pauline Funchain @funchainmd.bsky.social · 28/02/2026
Good afternoon Vancouver 🌞🏔️ It’s 2026 and melanoma data continue to move in TIL 🏋️‍♀️ @drbetofmdphd.bsky.social discusses 10 year melanoma survival data for patients who have experienced complete response with earlier versions of TIL #MovingTheGoalPosts #CMC26 @stanford-cancer.bsky.social
031 0
Pauline Funchain @funchainmd.bsky.social · 15/11/2025
Good morning Mountain View 🌞 Nothing like starting the day jumping into the great academic debate over surveillance strategies for uveal melanoma. Esp if one of the debaters is an old friend and colleague Arun Singh @clevelandclinic.bsky.social Whatever it takes to knock out cancer 🥊 #rarediseases
120 0
Pauline Funchain @funchainmd.bsky.social · 15/11/2025
Amazing night celebrating the inception of the Alan Adler Center for Ophthalmic Oncology and Prithvi Mruthyunjaya, the Alan Adler Professor of Ophthalmology @ Byers Eye and @stanford-cancer.bsky.social member 🍾🎊
010 0
Pauline Funchain @funchainmd.bsky.social · 05/11/2025
Is this explosive growth in publications good for science: Fabulous questions posed and thoughtful summary on the state of publications today by @kbibbinsdomingo.bsky.social editor in chief @jama.com Medicine Grand Rounds @stanfordmedicine.bsky.social
040 0
Pauline Funchain @funchainmd.bsky.social · 05/11/2025
🚨 irAE aficionados! This Friday! @aspire-cop.bsky.social is at @sitcancer.bsky.social 🥳 ⏱️4-6p 📍Chesapeake Rm 2-3 More details below:
011 0
Pauline Funchain @funchainmd.bsky.social · 04/11/2025
AI in Clinical Science - amazing data being presented today by @jason-fries.bsky.social Sylvia Plevritis @roxanadaneshjou.bsky.social @akshay-chaudhari.bsky.social but still feel like we are just barely cracking the egg in this field. So impatient for the omelette…! @stanford-cancer.bsky.social
042 0
Pauline Funchain @funchainmd.bsky.social · 04/11/2025
Ever wonder why our HLA specified cancer therapies are only for HLA02:01 thus far? @possuhuanglab.bsky.social presents the scope of the problem at the inaugural @stanford-cancer.bsky.social AI and Cancer Research Symposium 🧬
021 0
Pauline Funchain @funchainmd.bsky.social · 04/11/2025
Seeing the future: from Election Day straight to AI and Cancer Research @stanford-cancer.bsky.social Keynote speaker Michelle Mello @law.stanford.edu with involved Q&A over the use of AI in prior auth
020 0
Pauline Funchain @funchainmd.bsky.social · 22/10/2025
“A child does not pay for his mother’s milk.” 🙏 Profound global cancer lessons from Dr. Miriam Mutebi Nothing like #ESMO25 back-to-back with a deep dive into cancer in Africa to understand cancer as a truly 🌍 global effort @stanfordmedicine.bsky.social Grand Rounds 👏 @stanford-cancer.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 16/10/2025
Pledge allegiance to your hands, your team, your vibes/all the airports you have been/Caffeine, you’re mine/ it’s ‘bout to be the sleepless night/ because of ESMO #yayjetlag #LifeofanAcademicGirl
010 0
Pauline Funchain @funchainmd.bsky.social · 09/10/2025
The Mount Rushmore of @stanford-cancer.bsky.social leaders past and present at a fireside chat, reflecting on their career paths, their pivotal choices, how they maintain high achievement with non-academic life #Asilomar25
120 0
Pauline Funchain @funchainmd.bsky.social · 17/09/2025
Fangirling here - Sumbul Desai VP of Health at Apple, previously worked at Disney, now bringing access to health information to the masses with a small metal and glass box that sits on your wrist #MGR @stanforddeptmed.bsky.social
021 0
Pauline Funchain @funchainmd.bsky.social · 16/09/2025
#CCRTP25 cancer immunotherapy session covering the breadth of anti tumor immunity - immune tolerance incited by lymph node involvement @retickerflynn.bsky.social, cytokine conditioning of T cells - A Kalbasi, and synthetic engineering of cytokine receptors - K Daniels @stanford-cancer.bsky.social
020 0
Pauline Funchain @funchainmd.bsky.social · 16/09/2025
Good morning Redwood City 🌞 Rise and shine to Day 2 of the #CCRTP25 @stanford-cancer.bsky.social Still unbelievable to be colleagues with Dr Ron Levy and see how integrated and committed he is to educating the next generation of cancer researchers
030 0
Pauline Funchain @funchainmd.bsky.social · 15/09/2025
Great 💎s on GI cancers at #CCRTP25 @stanford-cancer.bsky.social @corsello.bsky.social -drug discovery w better yield from unexpected hits, then subsequently modified -negative results so important to publish -environmental factors like weight most likely culprits of young onset colon cancer
011 0
Pauline Funchain @funchainmd.bsky.social · 15/09/2025
So far we have talked about non smoking Asian females (lung cancer) and people in their 30s and 40s (colon cancer) and I’m feeling a bit targeted in the worst way 😂 #CCRTP25 @stanford-cancer.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 15/09/2025
The amazing breath of nicotine products today, with significantly higher amounts of nicotine than cigarettes, covered by keynote speaker Carly Kajiwara from the Halpern-Felsher Lab @stanford-cancer.bsky.social #CCRTP25
010 0
Pauline Funchain @funchainmd.bsky.social · 15/09/2025
Good morning Redwood City 🌞 Rise and shine for an action packed day at the Comprehensive Cancer Research Training Program @stanford-cancer.bsky.social - Day 1 of 2 for soaking in cancer research 🤓🥳
031 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Melanoma orals #8 ➡️ S2000 enco bini nivo vs ipi nivo in symptomatic melanoma brain mets ➡️First randomized trial in symptomatic brain mets ➡️Significant PFS improvement with triple therapy over ipi nivo ➡️No significant OS benefit Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social
040 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ ➡️ 63.3% for ipi/nivo first ➡️ 33.9% for dab/tram first Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
030 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ ➡️ 63.3% for ipi/nivo first ➡️ 33.9% for dab/tram first Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
020 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Melanoma orals #6 ➡️ ECOG 6194 ph II pembro + injectable TLR9 agonist vidutolimod in stage III melanoma pCR 71% MPR 79% 1 yr EFS 89% Me: pCR much higher than other studies but with an injectable agent very hard to interpret the systemic effect Ahmad Tarhini #ASCO25 @ascocancer.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Melanoma orals #4 ➡️ ph II neoadjuvant dostarlimab + anti TIM3 cobolimab in stage III melanoma D+C with mPR 51.9% with 1 yr EFS 92% Megan Mooradian @mgbresearch.bsky.social #ASCO25 @ascocancer.bsky.social
020 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Melanoma orals #4 ➡️ ph II neadjuvant anti TIGIT tiragolimab and atezolizumab in stage III melanoma ➡️47.7% pCR ➡️91.7% 12 m RFS for those with MPR ➡️no type 1 DM, AI Tina Heiken @mayocliniccancer.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
020 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Caroline Robert asks if we should move away from CTCAE grading of irAE in trials and acknowledge the AI (which she notes is more likely focal hypopit rather than AI) is actually a 6% rate of permanent medication-requiring disease #irAE #ASCO25 #melsm @ascocancer.bsky.social @aspire-cop.bsky.social
020 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Discussion of 1st set of melanoma orals by Ana Arance - Toxicities are the *key* challenge in the adjuvant setting and mitigation of #irAE are the priority in this setting #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Melanoma orals #3 ➡️ neoadjuvant pembro on stage II/III melanoma Stage IIC SLN positivity significantly different from historical controls; 2 yr RFS “high” Me: Intriguing but hard to understand if true impact given a (moving) historical control Georgios Karakousis #ASCO25 @ascocancer.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Melanoma oral #2 #ASCO25 Ph III adjuvant enco bini - Alex van Akkooi summarizes as a tolerable regimen @ascocancer.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Melanoma oral #1 #ASCO25 ➡️ ph III adj rela nivo vs nivo (RELATIVITY 098) - no difference in RFS, DMFS Presented by Georgina Long @melanomaau.bsky.social @ascocancer.bsky.social
020 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Where are TIL today, one year later? #ASCO25 ➡️4 year OS 22.2% ➡️front line with excellent ORR, although 12 month survival lower than checkpoint inhibition ➡️in real practice, multiple paths to, off, and after TIL for individual patients Don Lawrence @mgbresearch.bsky.social @ascocancer.bsky.social
030 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
Multiple new agents with mechanisms other than immunotherapies under investigation for metastatic melanoma: ➡️ new BRAF targeting agents ➡️ PRMT5 inhibition ➡️ ROR2 ADC -Meredith McKean, Sarah Cannon #ASCO25 @ascocancer.bsky.social
031 0
Pauline Funchain @funchainmd.bsky.social · 03/06/2025
AI imaging of skin cancer has good prediction but predictive power dropped in a larger pretesting dataset - important to check AI algorithms at multiple time points! Susan Swetter @stanford-cancer.bsky.social #ASCO25 @ascocancer.bsky.social
040 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Much less clarity on whether or not to continue systemic immunotherapy after pCR following neoadjuvant therapy The people have spoken, and they are undedecided - more work to do! #melsm #ASCO25
041 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Ever wonder how pathologists calculate neoadjuvant response metrics (% residual viable tumor, % necrosis, % regression)? Formulas and recommendations for standardized reporting 👇 Janis Taube @hopkinsmedicine.bsky.social #ASCO25 #melsm @ascocancer.bsky.social
030 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Neoadj ipi/nivo is clear winner in melanoma, prompting Genevieve Boland and Diwakar Davar to discuss the CONSTANT communication required between med onc/ surg onc (and relevant subspecialists) perioperatively to address ir-AI or colitis #ASCO25 #irAE @ascocancer.bsky.social @aspire-cop.bsky.social
040 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Melanoma rapid oral #9 ➡️ OBX-115, engineered TIL with membrane bound IL15 regulated with acetazolamide -for 6pt receiving RP2D, 67% ORR, 1 CR, 100% DCR -mDOR not reached Jason Chesney U Louisville and @drbetofmdphd.bsky.social @stanford-cancer.bsky.social #ASCO25 @ascocancer.bsky.social
073 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Melanoma rapid oral #8 ➡️ TIL product characteristics (cell types) that may predict outcome Me: Would be great to access a profile that saves patients from high toxicity profile but honestly would be hard to lose options Lilit Karapetyan @moffittnews.bsky.social #ASCO25 @ascocancer.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Rapid melanoma oral #7 ➡️ 5 year outcomes with lifileucel -mDOR 36.5m -31.3% of responders with sustained response -3 pts with PR that deepened after about a year -AEs within first 3 m and drop off dramatically Theresa Medina U Colo #ASCO25 @ascocancer.bsky.social
031 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Melanoma rapid oral #6 ➡️ neoadj lenvatinib + pembro in Merkel cell -57.7% pCR -50% at least 1 TRAE Thoughts - what are we gaining and at what cost? Will be interesting to see long term outcomes given MCC with higher rate of recurrence after CR from IO in stage IV #ASCO25 @ascocancer.bsky.social
020 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Melanoma rapid orals #5 ➡️ single dose of neoadj ipi 3 + nivo 1 with 59% major pathological response and 9% grade 3+ TRAE. CD8 PET not predictive. Sarah Lochrin @mskcc.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Rapid oral #4 adjuvant camrelizumab apatinib and temolozolamide in stage II/MM acral melanoma in a Chinese population with 25% pCR -so impt to understand different biologies by geography/population Lili Mao, Peking U #ASCO25 @ascocancer.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Melanoma rapid #3 ➡️ High fiber diet of 30-50g daily is tolerable, pCR 57% in neoadj group, grade 3+ irAE 28.8% Took 400 patients screened to enroll 45 🤔 Yiufan Qiu @mdanderson.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
021 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Phase II ipi nivo rela with IL6 inhibitor sarilumab with ORR 68% - highest reported with IO - and grade 3/4 irAEs 12% - lowest reported with combination IO Jan Mehnert @nyulangone.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
031 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Rapid oral #1 - DYP688, novel ADC in mUM, 11/64 pts with response, tolerable, many responses durable Matteo Carlino #ASCO25 @ascocancer.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Metastatic mucosal melanoma today: -combination immunotherapy shows lackluster efficacy -MEKi with 25% ORR -KIT + anti PD1 with 54.8% ORR -triplet ICI with 33% ORR -lenv pembro with 50% ORR -TIL with 50% ORR Jun Guo #ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social
062 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Adjuvant and neoadjuvant data for mucosal melanoma summarized by Jun Guo -adjuvant outcomes not as good as cutaneous -neoadjuvant approaches under study #ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social
010 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Swiftly moving from no options to what to do in what order with so many options - Marlana Orloff, Thomas Jefferson on metastatic uveal melanoma sequencing strategies #ASCO25 @ascocancer.bsky.social
020 0
Pauline Funchain @funchainmd.bsky.social · 02/06/2025
Acral melanoma pearls -adjuvant therapy not effective -targeted therapy with responses (not enough data to clearly choose IO vs targeted as 1L imho) -alternative regimens with efficacy in Asia (different biology than US?) Keri Kendra @ohiostatemed.bsky.social #ASCO25 @ascocancer.bsky.social
031 0